Microbion Corporation

Microbion Corporation is a clinical-stage pharmaceutical company focusing on developing therapeutic compounds for rare and serious diseases. The company's lead drug candidate, pravibismane, has received substantial support, totaling over $21 million in grants from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X. Pravibismane has been granted Orphan Drug, Fast Track, and QIDP designations by the FDA and is currently in clinical development for chronic lung diseases and chronic wounds and orthopedic infections. The drug's potent effectiveness against a broad spectrum of pathogens, including "superbugs" as identified by the US CDC, makes it a promising development in the battle against antibiotic resistance. Additionally, Microbion’s site-specific delivery approach is designed to achieve higher therapeutic concentrations at the site of infection and minimize the risk of antibiotic resistance. The company, founded in 2000 and headquartered in the United States, recently received a Venture - Series Unknown investment at 31 March 2021.